Disc Medicine, Inc. (IRON)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$78.47-5.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · IRON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
IRON — debt issuance
Dated 2026-10-22
Entry into a Material Definitive Agreement. On October 20, 2026, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) by the Company of 6,000,000 shares (the “Firm Shares”) of common stock o…
Why it matters: The early results linked DISC-3405 to fewer phlebotomies and hematocrit below 45%. More patients and longer follow-up can test that result.
Supportive ifThe planned update shows hematocrit below 45% and fewer phlebotomies. It also has more follow-up than the 13 Cohort A patients had at week 26.
Worry ifThe update shows group hematocrit of 45% or higher. Or it shows more phlebotomy use than the reported 0.6 events over 26 weeks.
Why it matters: The FDA decision will show whether bitopertin can move from trial results toward use in EPP and XLP.
Supportive ifThe FDA issues a decision by June 30, 2027, with no new safety concern or request that blocks approval.
Worry ifThe FDA rejects the NDA, asks for more trial data, or does not issue a decision by June 30, 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$160 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $435 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,077 loss on $10,000 · 40.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.